梅斯医学

订阅

MedSci主页 / 所有栏目 / 梅斯医学

肺栓塞病人低分子肝素抗凝期间需要TBNA时，低分子肝素什么时候停药及注意事项？

2021-08-26 MedSci原创 MedSci原创

肺栓塞支气管镜下
关注

支气管镜下诊疗技术临床应用问题回答

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906768, encodeId=73c91906e684c, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Mon Jul 11 23:56:32 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063255, encodeId=55ab1063255cc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c5608723, createdName=芳芳要加油呀, createdTime=Sat Oct 23 21:53:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460856, encodeId=cca01460856b1, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Sat Aug 28 01:56:32 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481461, encodeId=36fa14814612c, content=<a href='/topic/show?id=cf432615e79' target=_blank style='color:#2F92EE;'>#低分子肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26157, encryptionId=cf432615e79, topicName=低分子肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=192e7793966, createdName=jingyanzhu715_39486103, createdTime=Sat Aug 28 01:56:32 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011695, encodeId=c344101169512, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e75409349, createdName=ms4000000871644201, createdTime=Thu Aug 26 13:44:50 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2022-07-11 xlwang2691

    #注意事项#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1906768, encodeId=73c91906e684c, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Mon Jul 11 23:56:32 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063255, encodeId=55ab1063255cc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c5608723, createdName=芳芳要加油呀, createdTime=Sat Oct 23 21:53:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460856, encodeId=cca01460856b1, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Sat Aug 28 01:56:32 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481461, encodeId=36fa14814612c, content=<a href='/topic/show?id=cf432615e79' target=_blank style='color:#2F92EE;'>#低分子肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26157, encryptionId=cf432615e79, topicName=低分子肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=192e7793966, createdName=jingyanzhu715_39486103, createdTime=Sat Aug 28 01:56:32 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011695, encodeId=c344101169512, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e75409349, createdName=ms4000000871644201, createdTime=Thu Aug 26 13:44:50 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-10-23 芳芳要加油呀

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1906768, encodeId=73c91906e684c, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Mon Jul 11 23:56:32 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063255, encodeId=55ab1063255cc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c5608723, createdName=芳芳要加油呀, createdTime=Sat Oct 23 21:53:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460856, encodeId=cca01460856b1, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Sat Aug 28 01:56:32 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481461, encodeId=36fa14814612c, content=<a href='/topic/show?id=cf432615e79' target=_blank style='color:#2F92EE;'>#低分子肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26157, encryptionId=cf432615e79, topicName=低分子肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=192e7793966, createdName=jingyanzhu715_39486103, createdTime=Sat Aug 28 01:56:32 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011695, encodeId=c344101169512, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e75409349, createdName=ms4000000871644201, createdTime=Thu Aug 26 13:44:50 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-08-28 yinhl1980

    #停药#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1906768, encodeId=73c91906e684c, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Mon Jul 11 23:56:32 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063255, encodeId=55ab1063255cc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c5608723, createdName=芳芳要加油呀, createdTime=Sat Oct 23 21:53:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460856, encodeId=cca01460856b1, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Sat Aug 28 01:56:32 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481461, encodeId=36fa14814612c, content=<a href='/topic/show?id=cf432615e79' target=_blank style='color:#2F92EE;'>#低分子肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26157, encryptionId=cf432615e79, topicName=低分子肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=192e7793966, createdName=jingyanzhu715_39486103, createdTime=Sat Aug 28 01:56:32 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011695, encodeId=c344101169512, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e75409349, createdName=ms4000000871644201, createdTime=Thu Aug 26 13:44:50 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-08-28 jingyanzhu715_39486103

    #低分子肝素#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1906768, encodeId=73c91906e684c, content=<a href='/topic/show?id=6440650062f' target=_blank style='color:#2F92EE;'>#注意事项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65006, encryptionId=6440650062f, topicName=注意事项)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6ac207, createdName=xlwang2691, createdTime=Mon Jul 11 23:56:32 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063255, encodeId=55ab1063255cc, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c5608723, createdName=芳芳要加油呀, createdTime=Sat Oct 23 21:53:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460856, encodeId=cca01460856b1, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Sat Aug 28 01:56:32 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481461, encodeId=36fa14814612c, content=<a href='/topic/show?id=cf432615e79' target=_blank style='color:#2F92EE;'>#低分子肝素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26157, encryptionId=cf432615e79, topicName=低分子肝素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=192e7793966, createdName=jingyanzhu715_39486103, createdTime=Sat Aug 28 01:56:32 CST 2021, time=2021-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011695, encodeId=c344101169512, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17e75409349, createdName=ms4000000871644201, createdTime=Thu Aug 26 13:44:50 CST 2021, time=2021-08-26, status=1, ipAttribution=)]
    2021-08-26 ms4000000871644201

    学习

    0

相关资讯

王晓天：大隐静脉曲张术后肺栓塞问题的探讨

大隐静脉曲张是血管外科中最常见的疾病之一，也是血管外科中手术量最大的手术之一。然而，患者往往认为静脉曲张手术只是“小手术”，因此一旦出现严重的肺栓塞或因此而死亡，将导致医疗纠纷。

Eur Heart J：低死亡风险的肺栓塞患者右心室评估的临床意义

通过超声心动图、计算机断层扫描或BNP/NT-proBNP和肌钙蛋白水平升高评估的RVD与低风险急性PE患者的短期死亡相关。

J Thromb Haemost：癌症患者尸检时肺栓塞情况

在癌症患者尸检时，PE的比例是相当大的。虽然研究人群不能代表总体癌症人群，但这表明PE是癌症患者重要的并发症。

Lancet respir med：北美地区肺栓塞有关的死亡率变化趋势研究

总体上，北美肺栓塞有关的死亡率呈现下降趋势，加拿大达到一个平稳期，而在美国，年轻人和中年人中观察到了死亡率反弹增长。这一现象与其他心血管疾病死亡率的上升趋势相似，反映出美国民众危险因素暴露和医疗保健获

Eur Radiol: 双能CTA灌注缺损表现是否可提示肺栓塞患者预后不良？

双能CTA (DECTA)可以根据物质能量吸收的特征提示物质的组成，并已被用于检测PE。DECTA可以在不增加辐射剂量的情况下同时评估肺血管和实质内碘的分布。

JAMA Cardiol：4级肺栓塞临床概率评分(4PEPS)在减少肺栓塞过度影像学检查方面的应用

在减少影像学检查方面，4PEPS策略比之前提出的所有策略表现更好。